Coronavirus | Remdesivir shortage in Nagpur; Gadkari dials Sun Pharma chief

Mr. Gadkari also appealed to the people of Nagpur to follow all COVID-19 prevention protocols

April 11, 2021 05:35 pm | Updated 05:35 pm IST - Nagpur

Nitin Gadkari. File

Nitin Gadkari. File

Union minister Nitin Gadkari has called up Sun Pharma's chief to arrange for 10,000 injections of Remdesivir in Nagpur in view of a shortage of the medicine here in Maharashtra.

Remdesivir is considered a key anti-viral drug in the fight against COVID-19 , especially in adult patients with severe complications.

A press release from Mr. Gadkari's office on Saturday said the Lok Sabha member from Nagpur spoke to Sun Pharma's Managing Director Dilip Shanghvi over phone to inform him about the situation and appealed to him to make available the Remdesivir injections.

The pharma company chief assured Mr. Gadkari of making available 5,000 injections immediately on Saturday and the remaining 5,000 in next two-three days, the release said.

Mr. Gadkari also appealed to the people of Nagpur to follow all COVID-19 prevention protocols.

With Maharashtra witnessing a spurt in COVID-19 cases, Remdesivir injections are in high demand in the State.

Maharashtra Revenue Minister Balasaheb Thorat on Saturday said there is shortage of Remdesivir injections and the supply of vaccine doses was inadequate.

On Thursday, the state government capped the price of Remdesivir between ₹1,100 and ₹1,400 per vial and warned against its hoarding and black marketing.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.